Christopher Dittus, DO, MPH, is the editor of a book on rare lymphomas.
UNC Lineberger’s Christopher Dittus, DO, MPH.

UNC Lineberger’s Christopher Dittus, DO, MPH, assistant professor of medicine at UNC School of Medicine, is the editor of a new book that provides a comprehensive review of how to diagnose and manage rare lymphomas, with a focus on novel treatment approaches. UNC Lineberger faculty and trainees contributed chapters to the volume.

Novel Therapeutics for Rare Lymphomas” offers insights on new treatment modalities, including targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and chimeric antigen receptor T-cell (CAR-T) therapy, for rare subtypes of lymphoma, such as plasmablastic lymphoma, Waldenstrom’s macroglobulinemia and primary CNS lymphoma.

Because of their rarity, these diseases are often difficult to manage. Dittus said the purpose of the book is to increase the understanding of these diseases, with the goal of improving patient care.

In addition to Dittus, the other UNC Lineberger members who wrote chapters for the book are Anne Beaven, MD, Edith Bowers, MD, Catherine C. Coombs, MD, Yuri Fedoriw, MD, Natalie Grover, MD, Yara Park, MD, Raghuveer Ranganathan, MD, and Thomas C. Shea, MD. UNC hematology and oncology fellows Timothy Voorhees, MD, and Luis Malpica Castillo, MD, as well as UNC surgical pathology fellow Renee Betancourt, MD, were also authors. Additionally, faculty from nine other academic cancer centers contributed chapters.